

Title (en)

INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE

Title (de)

INHIBITOREN DER SAUREN SPHINGOMYELINASE ZUR PRÄVENTION UND BEHANDLUNG DER COVID-19-KRANKHEIT

Title (fr)

INHIBITEURS DE SPHINGOMYÉLINASE ACIDE POUR LA PRÉVENTION ET LE TRAITEMENT DE LA MALADIE COVID-19

Publication

EP 4171545 A1 20230503 (EN)

Application

EP 21735939 A 20210624

Priority

- EP 20305698 A 20200624
- EP 20306117 A 20200929
- US 202117146013 A 20210111
- EP 21305188 A 20210212
- EP 2021067427 W 20210624

Abstract (en)

[origin: WO2021260152A1] The present invention relates to the preventive and therapeutic uses of acid sphingomyelinase inhibitors (FIASMA) such as psychotropic medications and non-psychotropic compounds having FIASMA activity, for lowering the risk of death and/or intubation in patient suffering from a viral infection caused by at least one betacoronavirus, in particular by the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).

IPC 8 full level

A61K 31/35 (2006.01); **A61K 31/137** (2006.01); **A61K 31/138** (2006.01); **A61K 31/15** (2006.01); **A61K 31/165** (2006.01); **A61K 31/232** (2006.01); **A61K 31/343** (2006.01); **A61K 31/381** (2006.01); **A61K 31/4406** (2006.01); **A61K 31/443** (2006.01); **A61K 31/445** (2006.01); **A61K 31/454** (2006.01); **A61K 31/4965** (2006.01); **A61K 31/497** (2006.01); **A61K 31/55** (2006.01)

CPC (source: EP IL)

A61K 31/136 (2013.01 - EP IL); **A61K 31/137** (2013.01 - EP IL); **A61K 31/138** (2013.01 - EP IL); **A61K 31/215** (2013.01 - EP IL); **A61K 31/216** (2013.01 - EP IL); **A61K 31/223** (2013.01 - EP IL); **A61K 31/343** (2013.01 - EP IL); **A61K 31/382** (2013.01 - EP IL); **A61K 31/401** (2013.01 - EP IL); **A61K 31/403** (2013.01 - EP IL); **A61K 31/4184** (2013.01 - EP IL); **A61K 31/437** (2013.01 - EP IL); **A61K 31/4422** (2013.01 - EP IL); **A61K 31/445** (2013.01 - EP IL); **A61K 31/4453** (2013.01 - EP IL); **A61K 31/4458** (2013.01 - EP IL); **A61K 31/4468** (2013.01 - EP IL); **A61K 31/4535** (2013.01 - EP IL); **A61K 31/454** (2013.01 - EP IL); **A61K 31/4545** (2013.01 - EP IL); **A61K 31/46** (2013.01 - EP IL); **A61K 31/473** (2013.01 - EP IL); **A61K 31/4748** (2013.01 - EP IL); **A61K 31/4965** (2013.01 - EP IL); **A61K 31/497** (2013.01 - EP IL); **A61K 31/498** (2013.01 - EP IL); **A61K 31/5415** (2013.01 - EP IL); **A61K 31/551** (2013.01 - EP IL); **A61K 31/58** (2013.01 - EP IL)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

WO 2021260152 A1 20211230; AU 2021295456 A1 20230223; BR 112022026283 A2 20230307; CA 3183547 A1 20211230; EP 4171545 A1 20230503; IL 299435 A 20230201; KR 20230043849 A 20230331; MX 2023000154 A 20230424

DOCDB simple family (application)

EP 2021067427 W 20210624; AU 2021295456 A 20210624; BR 112022026283 A 20210624; CA 3183547 A 20210624; EP 21735939 A 20210624; IL 29943522 A 20221222; KR 20237002857 A 20210624; MX 2023000154 A 20210624